Jeff Hatfield, Vividion CEO

‘Pluck those di­a­monds’: Bay­er’s Vi­vid­ion eyes up to nine on­col­o­gy tar­gets from Duke spin­out

Af­ter snap­ping up Vi­vid­ion be­fore it could jump on­to Nas­daq last Au­gust, Bay­er’s pre­clin­i­cal ‘arms-length’ sub­sidiary is bet­ting on a rel­a­tive­ly un­known North Car­oli­na up­start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.